Erasca Misrepresentation Lawsuit

Erasca, Inc.'s common stock has been the subject of a class action lawsuit filed on behalf of investors who purchased shares between January 14, 2025 and April 26, 2026. The complaint alleges that Erasca made false and misleading statements about its lead oncology drug candidate, ERAS-0015, during this period. Specifically, it is claimed that the company exaggerated preclinical results compared to a competing drug candidate from Revolution Medicines, while failing to disclose potential patent and trade secret disputes. As a result of these alleged misrepresentations, investors may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. Investors who purchased Erasca common stock during the specified period are advised to join the class action by visiting https://rosenlegal.com/cases/erasca-inc/join or contacting Phillip Kim, Esq., toll-free at 866-767-3653 or via email at [email protected]. The deadline for serving as lead plaintiff is August 10, 2026.